Toll Free Number Toll Free: 1800 103 1369 Email Us Email Us: customercare@canmoney.in

Markets

Market

News Details

(05/11/2026 09:52)

Dr. Reddy’s gets marketing authorisation for generic semaglutide injection in Brazil

Dr. Reddy’s Laboratories has received marketing authorisation from Brazil’s National Health Surveillance Agency (ANVISA) for its generic semaglutide injection to treat adults with inadequately controlled type 2 diabetes.

The drug will be available in pre-filled, multi-dose injectable pens in two strengths – 2 mg/1.5 mL and 4 mg/3 mL – for once-weekly administration.

Brazil has around 16.6 million adults living with diabetes, making it the sixth-largest country globally in terms of diabetic population. The country's semaglutide market for diabetes treatment is estimated at approximately USD 244.6 million.

Dr. Reddy’s said it plans to launch the product in Brazil in partnership with Ach‚, further expanding its global semaglutide strategy and improving access to diabetes treatment.